CURIS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
CURIS, INC. (CRIS) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$14.65 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-26.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-03-26
- CURIS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$1.93M.
- CURIS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$4.90M, a 121.17% decline year-over-year.
- CURIS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $5.73M.
- CURIS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$13.55M, a 182.74% decline year-over-year.
- CURIS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$14.65M, a 219.61% decline from fiscal 2017.
- CURIS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $12.25M.
- CURIS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$7.05M, a 127.83% decline from fiscal 2015.
- CURIS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $25.34M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | -$1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | -$6.83M derived: sum of 2 quarters · filed 2019-03-26 | -$1.10M derived: sum of 3 quarters · filed 2019-03-26 | -$14.65M 10-K · filed 2019-03-26 | |||
| 2018-09-30 | -$4.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $825.00K derived: sum of 2 quarters · filed 2018-11-01 | -$12.73M 10-Q · filed 2018-11-01 | -$24.28M derived: sum of 4 quarters · filed 2019-03-26 | |||
| 2018-06-30 | $5.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$7.82M 10-Q · filed 2018-08-02 | -$19.37M derived: sum of 3 quarters · filed 2019-03-26 | $3.79M derived: sum of 4 quarters · filed 2019-03-26 | |||
| 2018-03-31 | -$13.55M 10-Q · filed 2018-05-03 | -$25.10M derived: sum of 2 quarters · filed 2019-03-26 | -$1.94M derived: sum of 3 quarters · filed 2019-03-26 | -$17.68M derived: sum of 4 quarters · filed 2019-03-26 | |||
| 2017-12-31 | -$11.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $11.61M derived: sum of 2 quarters · filed 2019-03-26 | -$4.13M derived: sum of 3 quarters · filed 2019-03-26 | $12.25M 10-K · filed 2019-03-26 | |||
| 2017-09-30 | $23.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $7.42M derived: sum of 2 quarters · filed 2018-11-01 | $23.80M 10-Q · filed 2018-11-01 | $29.17M derived: sum of 4 quarters · filed 2018-11-01 | |||
| 2017-06-30 | -$15.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $639.00K 10-Q · filed 2018-08-02 | $6.01M derived: sum of 3 quarters · filed 2018-08-02 | $18.03M derived: sum of 4 quarters · filed 2018-08-02 | |||
| 2017-03-31 | $16.38M 10-Q · filed 2018-05-03 | $21.75M derived: sum of 2 quarters · filed 2018-05-03 | $33.77M derived: sum of 3 quarters · filed 2018-05-03 | $27.73M derived: sum of 4 quarters · filed 2018-05-03 | |||
| 2016-12-31 | $5.37M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $17.39M derived: sum of 2 quarters · filed 2018-03-08 | $11.35M derived: sum of 3 quarters · filed 2018-03-08 | -$7.05M 10-K · filed 2018-03-08 | |||
| 2016-09-30 | $12.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $5.98M derived: sum of 2 quarters · filed 2017-11-07 | -$12.42M 10-Q · filed 2017-11-07 | -$7.99M derived: sum of 4 quarters · filed 2018-03-08 | |||
| 2016-06-30 | -$6.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$24.45M 10-Q · filed 2017-08-03 | -$20.02M derived: sum of 3 quarters · filed 2018-03-08 | -$22.84M derived: sum of 4 quarters · filed 2018-03-08 | |||
| 2016-03-31 | -$18.40M 10-Q · filed 2017-05-04 | -$18.40M 10-Q · filed 2016-05-09 | -$13.97M derived: sum of 2 quarters · filed 2018-03-08 | -$16.79M derived: sum of 3 quarters · filed 2018-03-08 | -$8.78M derived: sum of 4 quarters · filed 2018-03-08 | ||
| 2015-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $1.61M derived: sum of 2 quarters · filed 2018-03-08 | $9.62M derived: sum of 3 quarters · filed 2018-03-08 | $25.34M 10-K · filed 2018-03-08 | $25.34M 10-K · filed 2016-02-29 | ||
| 2015-09-30 | -$2.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $5.19M derived: sum of 2 quarters · filed 2016-11-03 | $20.91M 10-Q · filed 2016-11-03 | $20.91M 10-Q · filed 2015-11-09 | $20.73M derived: sum of 4 quarters · filed 2017-03-09 | ||
| 2015-06-30 | $8.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $23.74M 10-Q · filed 2016-08-04 | $23.55M derived: sum of 3 quarters · filed 2017-03-09 | $21.33M derived: sum of 4 quarters · filed 2017-03-09 | |||
| 2015-03-31 | $15.72M 10-Q · filed 2016-05-09 | $15.53M derived: sum of 2 quarters · filed 2017-03-09 | $13.31M derived: sum of 3 quarters · filed 2017-03-09 | $15.56M derived: sum of 4 quarters · filed 2017-03-09 | |||
| 2014-12-31 | -$185.98K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | -$2.41M derived: sum of 2 quarters · filed 2017-03-09 | -$160.38K derived: sum of 3 quarters · filed 2017-03-09 | -$1.84M 10-K · filed 2017-03-09 | -$1.84M 10-K · filed 2015-02-24 | ||
| 2014-09-30 | -$2.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $25.60K derived: sum of 2 quarters · filed 2015-11-09 | -$1.66M 10-Q · filed 2015-11-09 | -$5.85M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $564.87K 10-Q · filed 2014-08-07 | -$3.62M derived: sum of 3 quarters · filed 2016-02-29 | $413.42K derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | -$1.68M 10-Q · filed 2015-05-07 | -$5.87M derived: sum of 2 quarters · filed 2016-02-29 | -$1.84M derived: sum of 3 quarters · filed 2016-02-29 | -$1.81M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | -$4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$151.45K derived: sum of 2 quarters · filed 2016-02-29 | -$127.49K derived: sum of 3 quarters · filed 2016-02-29 | -$3.16M 10-K · filed 2016-02-29 | |||
| 2013-09-30 | $4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $4.06M derived: sum of 2 quarters · filed 2014-11-10 | $1.03M 10-Q · filed 2014-11-10 | $5.97M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2013-06-30 | $23.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$3.00M 10-Q · filed 2014-08-07 | $1.93M derived: sum of 3 quarters · filed 2015-02-24 | -$2.35M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2013-03-31 | -$3.03M 10-Q · filed 2014-05-09 | $1.91M derived: sum of 2 quarters · filed 2015-02-24 | -$2.37M derived: sum of 3 quarters · filed 2015-02-24 | -$4.97M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2012-12-31 | $4.94M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $658.05K derived: sum of 2 quarters · filed 2015-02-24 | -$1.94M derived: sum of 3 quarters · filed 2015-02-24 | -$2.37M 10-K · filed 2015-02-24 | |||
| 2012-09-30 | -$4.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$6.88M derived: sum of 2 quarters · filed 2013-11-12 | -$7.31M 10-Q · filed 2013-11-12 | -$4.07M derived: sum of 4 quarters · filed 2014-03-13 | |||
| 2012-06-30 | -$2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$3.03M 10-Q · filed 2013-08-08 | $205.40K derived: sum of 3 quarters · filed 2014-03-13 | $5.30M derived: sum of 4 quarters · filed 2014-03-13 | |||
| 2012-03-31 | -$432.48K 10-Q · filed 2013-05-09 | $2.80M derived: sum of 2 quarters · filed 2014-03-13 | $7.90M derived: sum of 3 quarters · filed 2014-03-13 | $3.57M derived: sum of 4 quarters · filed 2014-03-13 | |||
| 2011-12-31 | $3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | $8.33M derived: sum of 2 quarters · filed 2014-03-13 | $4.00M derived: sum of 3 quarters · filed 2014-03-13 | $7.29M 10-K · filed 2014-03-13 | |||
| 2011-09-30 | $5.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $765.01K derived: sum of 2 quarters · filed 2012-11-06 | $4.06M 10-Q · filed 2012-11-06 | $270.27K derived: sum of 4 quarters · filed 2013-03-13 | |||
| 2011-06-30 | -$4.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$1.03M 10-Q · filed 2012-08-09 | -$4.82M derived: sum of 3 quarters · filed 2013-03-13 | -$4.11M derived: sum of 4 quarters · filed 2013-03-13 | |||
| 2011-03-31 | $3.29M 10-Q · filed 2012-05-10 | -$494.74K derived: sum of 2 quarters · filed 2013-03-13 | $213.40K derived: sum of 3 quarters · filed 2013-03-13 | ||||
| 2010-12-31 | -$3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-13 | -$3.08M derived: sum of 2 quarters · filed 2013-03-13 | $551.12K 10-K · filed 2013-03-13 | ||||
| 2010-09-30 | $708.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $4.34M 10-Q · filed 2011-10-31 | |||||
| 2010-06-30 | $3.63M 10-Q · filed 2011-08-04 | ||||||
| 2009-12-31 | -$2.88M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |